Open AccessBleeding risk with concomitant use of tirofiban and third-generation P2Y12 receptor antagonists in patients with acute myocardial infarction: A real-life data
Author(s) -
Mustafa Kürşat Tigen,
M. Ozdil,
Altuğ Çinçin,
Emre Gürel,
Murat Sünbül,
Anıl Şahin,
Tuba Bayram Guctekin,
Zekeriya Doğan,
Nurten Sayar,
Beste Özben
Publication year - 2021
Publication title -
pubmed central
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.364
H-Index - 28
eISSN - 2149-2271
DOI - 10.5152/anatoljcardiol.2021.27974
Subject(s) - ticagrelor , medicine , tirofiban , clopidogrel , prasugrel , acute coronary syndrome , aspirin , concomitant , myocardial infarction , p2y12 , cardiology , anesthesia , percutaneous coronary intervention
Combination of dual antiplatelet therapy (DAPT) with glycoprotein (GP) IIb/IIIa inhibitors can increase bleeding risk. In this study, we aimed to investigate bleeding complications of different DAPTs with concomitant tirofiban use in patients with acute coronary syndrome (ACS).